Latest / DDReg Knowledge Capsule / Mastering Global CMC Variations & Life Cycle Management

Transcript

Mastering Global CMC Variations & Life Cycle Management · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to D-DRAG Knowledge Capsule. Imagine for a second that
• 0:03
  Speaker 1: you produce like a life-saving blood pressure medication.
• 0:07
  Speaker 2: Okay, a pretty high-stakes product.
• 0:09
  Speaker 1: Exactly. And you've just made what seems like a completely
• 0:12
  Speaker 1: invisible operational tweak. You change one specific microfilter in your
• 0:16
  Speaker 1: manufacturing lab, a change that actually makes the drug purer, safer,
• 0:21
  Speaker 1: and even faster to produce.
• 0:23
  Speaker 2: Sounds like a win across the board.
• 0:25
  Speaker 1: Right. So you sign off on the engineering report, the
• 0:27
  Speaker 1: new filter goes in, and you consider the job completely done.
• 0:29
  Speaker 2: Yes.
• 0:30
  Speaker 1: But here's the catch. Because of that one single filter,
• 0:33
  Speaker 1: your drug is suddenly considered an unapproved illegal product in
• 0:37
  Speaker 1: like 15 different countries.
• 0:39
  Speaker 2: Oh, wow.
• 0:39
  Speaker 1: Yeah. Your entire global supply chain just grinds to an
• 0:42
  Speaker 1: immediate screeching halt.
• 0:44
  Speaker 2: Which is, you know, the ultimate paradox of the pharmaceutical industry.
• 0:48
  Speaker 2: The physical science happening inside the four walls of your
• 0:50
  Speaker 2: manufacturing plant can be perfectly controlled, sure. But the moment
• 0:54
  Speaker 2: that product crosses a border... the reality of what that
• 0:57
  Speaker 2: product legally is completely fractures.
• 1:00
  Speaker 1: And this deep dive is going straight into that fracture. Yeah.
• 1:04
  Speaker 1: We were exploring the hidden, hyper-complex world of post-approval pharmaceutical changes,
• 1:09
  Speaker 1: and we're pulling directly from the Global Variation Management Post-Approval
• 1:14
  Speaker 1: Change Guide by D-Dreg Pharma.
• 1:16
  Speaker 2: It's such a fascinating source document.
• 1:18
  Speaker 1: It really is. Our mission today is to understand why
• 1:21
  Speaker 1: a tiny internal update splinters into dozens of distinct regulatory
• 1:26
  Speaker 1: battles across the globe. We're going to look at the
• 1:29
  Speaker 1: massive compliance risks involved and, you know, how the smartest
• 1:32
  Speaker 1: companies are actually managing all this chaos.
• 1:35
  Speaker 2: Because to understand the sheer scale of the problem, you
• 1:37
  Speaker 2: really have to look at how we define a change
• 1:39
  Speaker 2: in the first place. Scientifically, changing that microfilter is just
• 1:43
  Speaker 2: one event, right?
• 1:44
  Speaker 1: Right. It's one physical action.
• 1:46
  Speaker 2: Exactly. Your chemistry team validates it. You update your internal
• 1:50
  Speaker 2: quality systems. And the underlying molecule is identical. I mean,
• 1:53
  Speaker 2: the safety profile might even be improved, but regulatorily. There
• 1:57
  Speaker 2: is no such thing as a global scientific reality.
• 2:00
  Speaker 1: Meaning there isn't one universal law.
• 2:02
  Speaker 2: No, not at all. Global health authorities simply do not
• 2:06
  Speaker 2: share a unified legal framework.
• 2:08
  Speaker 1: I want to move away from the usual way people
• 2:10
  Speaker 1: describe this, which is usually comparing it to getting like
• 2:14
  Speaker 1: a building permit from a bunch of different city councils.
• 2:17
  Speaker 1: That just feels way too administrative.
• 2:19
  Speaker 2: Yeah, it doesn't quite capture the technical complexity.
• 2:22
  Speaker 1: Right. It's really more like pushing a global software update,
• 2:25
  Speaker 1: like a new iOS version. You have one core piece
• 2:28
  Speaker 1: of code, which is the science, but you are trying
• 2:32
  Speaker 1: to push it to millions of devices operating on totally
• 2:36
  Speaker 1: different cellular networks in different countries, all of which have
• 2:40
  Speaker 1: completely different data privacy laws and hardware constraints.
• 2:44
  Speaker 2: Oh, that's a really good way to look at it.
• 2:45
  Speaker 1: Thanks. I mean, the code is identical. But the deployment
• 2:49
  Speaker 1: environment dictates whether it works or totally crashes.
• 2:51
  Speaker 2: That is a highly accurate way to frame it because
• 2:53
  Speaker 2: it highlights the friction between the core logic and the
• 2:56
  Speaker 2: local ecosystem. And if we connect this to the bigger picture,
• 3:00
  Speaker 2: let's just look at the European Union versus the U.S.
• 3:02
  Speaker 2: FDA to see how that friction actually plays out.
• 3:05
  Speaker 1: Okay, let's do it.
• 3:06
  Speaker 2: So the EU manages this deployment through a highly specific
• 3:10
  Speaker 2: tiered variations framework. It's designed to triage the regulatory workload.
• 3:15
  Speaker 2: They categorize changes into type IA, type IB, and type
• 3:19
  Speaker 2: 2 variations, mostly based on the perceived risk to the patient.
• 3:24
  Speaker 1: Let's actually break those categories down because the DD-REG guide
• 3:27
  Speaker 1: mentions that the EU just applied new variation guidelines on
• 3:30
  Speaker 1: January 15, 2026. So what do those tiers actually mean
• 3:34
  Speaker 1: in practice today?
• 3:36
  Speaker 2: Sure. So a type IA variation is essentially just an
• 3:38
  Speaker 2: administrative update. Think of it as a do and tell procedure.
• 3:42
  Speaker 1: Do and tell. OK, so act first.
• 3:43
  Speaker 2: Exactly. It has almost zero impact on the quality or
• 3:46
  Speaker 2: safety of the drug like changing the phone number of
• 3:50
  Speaker 2: the marketing authorization holder. You make the change and then
• 3:53
  Speaker 2: you tell the authority.
• 3:54
  Speaker 1: Makes sense. What of type IV?
• 3:56
  Speaker 2: Type IV is sort of the default category for minor changes.
• 3:59
  Speaker 2: This operates on a tell, wait and do model, which
• 4:02
  Speaker 2: we'll definitely explore more deeply in a moment.
• 4:04
  Speaker 1: Wait, tell, wait and do.
• 4:05
  Speaker 2: Right. Essentially, you notify them of the process tweak, you
• 4:08
  Speaker 2: wait for a specific period, and if they don't object,
• 4:10
  Speaker 2: you go ahead and proceed.
• 4:11
  Speaker 1: Got it. And then there's type 2.
• 4:12
  Speaker 2: Yeah, type 2 is the big one. It's a major change.
• 4:15
  Speaker 2: This is for something that significantly alters a quality, safety,
• 4:18
  Speaker 2: or efficacy profile of the drug.
• 4:20
  Speaker 1: Like adding a completely new manufacturing site.
• 4:22
  Speaker 2: Exactly, or fundamentally altering the active ingredient synthesis. For a
• 4:27
  Speaker 2: type 2, you are strictly in a prior approval situation.
• 4:31
  Speaker 2: You submit extensive data... and you cannot move a single
• 4:34
  Speaker 2: muscle until the European Medicines Agency explicitly grants you authorization.
• 4:39
  Speaker 1: Okay, so you have this very structured, tiered system in Europe.
• 4:42
  Speaker 1: But then you look over at the United States, and
• 4:44
  Speaker 1: the FDA is evaluating the exact same microfilter change through
• 4:48
  Speaker 1: an entirely different lens.
• 4:50
  Speaker 2: Yeah, the FDA relies on a completely distinct reporting framework.
• 4:53
  Speaker 2: It's built around NDAs, which are new drug applications for novel,
• 4:58
  Speaker 2: brand-name drugs, And ANDAs, the abbreviated new drug applications used
• 5:02
  Speaker 2: for generics.
• 5:03
  Speaker 1: Why do they split them up like that?
• 5:04
  Speaker 2: It's all based on the burden of proof. An NDA
• 5:07
  Speaker 2: has massive original safety and clinical data behind it. But
• 5:11
  Speaker 2: an ANDA, it primarily relies on just proving the generic
• 5:14
  Speaker 2: is bioequivalent to the original drug.
• 5:17
  Speaker 1: Ah, meaning a change to a brand name drug might
• 5:20
  Speaker 1: trigger a totally different risk assessment than the exact same
• 5:24
  Speaker 1: change made to a generic version.
• 5:26
  Speaker 2: Precisely the issue. And based on that assessment, the FDA
• 5:30
  Speaker 2: uses its own terminology. They might demand a prior approval supplement,
• 5:34
  Speaker 2: which is akin to the EU's type 2. Right. Or
• 5:37
  Speaker 2: they might allow what's called a CBE, changes being affected.
• 5:41
  Speaker 2: There is a CBE-30, where you submit the supplement and
• 5:44
  Speaker 2: have to wait 30 days before distributing the drug.
• 5:46
  Speaker 1: Wait, there's a zero version too, right?
• 5:48
  Speaker 2: Yeah, the CBE-0. With that one, you can distribute the
• 5:51
  Speaker 2: drug the very moment the FDA receives your paperwork. And
• 5:55
  Speaker 2: if the change is incredibly minor, it might just be
• 5:57
  Speaker 2: logged in an annual report.
• 5:59
  Speaker 1: Wow. So the underlying chemistry hasn't changed. The manufacturing tweak
• 6:03
  Speaker 1: is completely identical. But the operational reality is that a
• 6:06
  Speaker 1: company might be waiting six months for a formal approval
• 6:08
  Speaker 1: in Europe while legally distributing the updated product in the U.S.
• 6:12
  Speaker 1: on day zero.
• 6:13
  Speaker 2: Which leads us to the most dangerous operational trap a
• 6:16
  Speaker 2: pharmaceutical company can fall into. Global change management teams can
• 6:20
  Speaker 2: never assume a classification from one jurisdiction translates to another.
• 6:24
  Speaker 2: You just can't do it.
• 6:25
  Speaker 1: So no copy pasting.
• 6:27
  Speaker 2: Exactly. You cannot look at a spreadsheet, see the EU
• 6:31
  Speaker 2: called it a type IB, and just assume you can
• 6:34
  Speaker 2: file the equivalent minor change pathway in Japan or Brazil.
• 6:38
  Speaker 2: The sovereign risk assessments are completely decoupled.
• 6:41
  Speaker 1: Okay, let's unpack this. Because if you can't translate classifications,
• 6:45
  Speaker 1: how do you actually execute a change without throwing your
• 6:48
  Speaker 1: entire supply chain into a brick wall.
• 6:50
  Speaker 2: It's a massive challenge.
• 6:52
  Speaker 1: The source guide highlights a really massive, incredibly common mistake
• 6:56
  Speaker 1: companies make here. They draft a memo saying, hey, we
• 6:59
  Speaker 1: are updating the manufacturing process. They send it to their
• 7:02
  Speaker 1: regional affiliates, and they let those local teams interpret the
• 7:05
  Speaker 1: change completely independently right from the start.
• 7:08
  Speaker 2: And that decentralized approach is the genesis of all the fragmentation.
• 7:12
  Speaker 2: I mean, if you let 50 local regulatory teams look
• 7:15
  Speaker 2: at a manufacturing update in isolation, you end up with
• 7:17
  Speaker 2: 50 different narratives.
• 7:19
  Speaker 1: Right. Like your team in Canada might officially file it
• 7:21
  Speaker 1: as a site transfer. Meanwhile, your team in Australia translates
• 7:25
  Speaker 1: it as a manufacturing process change.
• 7:28
  Speaker 2: Yes. And your team in South Korea submits a massive
• 7:31
  Speaker 2: data package calling it a specification update.
• 7:35
  Speaker 1: So now the company is forced to answer the exact
• 7:37
  Speaker 1: same fundamental scientific questions from different global health authorities... but
• 7:42
  Speaker 1: in completely different contexts with totally mismatched supporting documents.
• 7:47
  Speaker 2: It just creates a labyrinth of unnecessary risk. This is
• 7:51
  Speaker 2: exactly why D-Drag strongly advocates for a globally-led four-step model
• 7:56
  Speaker 2: to prevent the narrative from splintering like that.
• 7:58
  Speaker 1: Let's go through the model. The sequence is critical, right?
• 8:00
  Speaker 2: Super critical. It begins with step one, which is creating
• 8:03
  Speaker 2: a single global change record. Before any local affiliate files
• 8:07
  Speaker 2: a single piece of paper, you have to establish a
• 8:09
  Speaker 2: master baseline.
• 8:10
  Speaker 1: So everyone is starting from the same facts.
• 8:12
  Speaker 2: Right. You document the current approved state across the board,
• 8:15
  Speaker 2: the proposed future state, and the explicit rationale for the change.
• 8:19
  Speaker 1: Okay, so you lock in the definition of what is
• 8:21
  Speaker 1: actually happening. Then you move to step two, which is
• 8:25
  Speaker 1: establishing the global scientific justification. The idea here is to
• 8:30
  Speaker 1: lock in the science before you deal with the administrative politics.
• 8:33
  Speaker 2: Yes.
• 8:34
  Speaker 1: But how does a company actually build a scientific package
• 8:38
  Speaker 1: that satisfies 50 different countries with 50 different standards?
• 8:42
  Speaker 2: By designing for the worst case scenario.
• 8:44
  Speaker 1: Oh, interesting. How so?
• 8:45
  Speaker 2: Well, the chemistry, manufacturing and controls team, the CMC team,
• 8:50
  Speaker 2: they look across all the global markets where the drug
• 8:52
  Speaker 2: is sold. And they identify the authority with the absolute
• 8:55
  Speaker 2: strictest evidence requirement for this specific change.
• 8:59
  Speaker 1: Wow, I see.
• 9:00
  Speaker 2: Then they build the core scientific dossier to satisfy that
• 9:03
  Speaker 2: specific highest standard. That comprehensive data package becomes the controlled
• 9:08
  Speaker 2: scientific core. It is untouchable.
• 9:11
  Speaker 1: That makes perfect sense. If you clear the highest hurdle,
• 9:13
  Speaker 1: you inherently clear all the lower ones, provided you don't
• 9:16
  Speaker 1: alter the core data.
• 9:17
  Speaker 2: Exactly. Which brings us to step three, which is mapping
• 9:21
  Speaker 2: every single affected marketing authorization. And the guide points out
• 9:25
  Speaker 2: this has to be incredibly granular.
• 9:27
  Speaker 1: Why so granular?
• 9:28
  Speaker 2: It has to be because regulatory reality is localized all
• 9:32
  Speaker 2: the way down to the condition level. You have to
• 9:34
  Speaker 2: map the product to the specific market, to the specific authorization,
• 9:38
  Speaker 2: down to the currently approved condition.
• 9:41
  Speaker 1: Give me an example of how that goes wrong.
• 9:43
  Speaker 2: Sure. You might think you are changing from supplier A
• 9:46
  Speaker 2: to supplier B globally, but when you actually map it out,
• 9:50
  Speaker 2: you might discover that in Mexico, the registered supplier on
• 9:54
  Speaker 2: file is still actually supplier C from some legacy filing
• 9:58
  Speaker 2: five years ago.
• 9:58
  Speaker 1: Oh, wow. So you can't propose a future state if
• 10:02
  Speaker 1: your baseline assumes a reality that doesn't legally exist in
• 10:05
  Speaker 1: that specific country.
• 10:06
  Speaker 2: Exactly the problem. So only after you have established the
• 10:09
  Speaker 2: global change record, locked the core science, and mapped the
• 10:12
  Speaker 2: localized reality, do you finally move to step four.
• 10:15
  Speaker 1: And step four is where you let the local teams
• 10:17
  Speaker 1: back in.
• 10:18
  Speaker 2: Yes. Step four is where you finally allow the regional
• 10:20
  Speaker 2: teams to perform their local regulatory classification. They take the
• 10:24
  Speaker 2: locked science, and then they determine their local reporting category
• 10:27
  Speaker 2: and their submission timing.
• 10:29
  Speaker 1: And managing this whole flow requires what the guide calls
• 10:33
  Speaker 1: a global regulatory variation matrix. It's essentially the command center
• 10:38
  Speaker 1: for the change.
• 10:39
  Speaker 2: Yeah, that's a good way to put it.
• 10:40
  Speaker 1: And looking at the required fields for this matrix, you know,
• 10:43
  Speaker 1: the global change ID, the local classification, the dossier sections,
• 10:47
  Speaker 1: the most fascinating operational metric isn't actually the approval date.
• 10:52
  Speaker 2: No, tracking only the formal approval date is a massive
• 10:55
  Speaker 2: logistical error. The critical metric you actually have to track
• 10:58
  Speaker 2: is called implementation eligibility.
• 11:01
  Speaker 1: Why is eligibility a more powerful metric than a formal approval?
• 11:04
  Speaker 2: Because a physical signature from a regulator is not always
• 11:07
  Speaker 2: the legal threshold for action. Let's revisit the EU's type
• 11:11
  Speaker 2: IB variation, right?
• 11:13
  Speaker 1: The one that operates on the tell, wait, and do model.
• 11:15
  Speaker 2: Exactly. When a company notifies the European Medicines Agency of
• 11:18
  Speaker 2: a type IB change, a 30-day clock starts.
• 11:22
  Speaker 1: Okay.
• 11:22
  Speaker 2: If the EMA does not raise an objection within those
• 11:24
  Speaker 2: 30 days, the company is legally eligible to implement the
• 11:28
  Speaker 2: change on day 31.
• 11:30
  Speaker 1: Wait, so you literally just run out the clock.
• 11:32
  Speaker 2: Yeah.
• 11:32
  Speaker 1: There's no official certificate of approval arriving in the mail.
• 11:35
  Speaker 2: None. Not at all. But if you cross-reference that with
• 11:39
  Speaker 2: a market that requires a prior approval for the exact
• 11:43
  Speaker 2: same change, you are waiting for a formal physical document there. Right.
• 11:47
  Speaker 2: So if your global matrix is strictly programmed to wait
• 11:51
  Speaker 2: for an approval date field to be populated before you
• 11:53
  Speaker 2: notify your supply chain, you are going to needlessly freeze
• 11:57
  Speaker 2: your European rollout for weeks or even months just waiting
• 12:01
  Speaker 2: for a document that is never going to come.
• 12:02
  Speaker 1: Wow.
• 12:03
  Speaker 2: You have to track when you are legally authorized to
• 12:06
  Speaker 2: act market by market.
• 12:07
  Speaker 1: Here's where it gets really interesting. The pharmaceutical industry is
• 12:10
  Speaker 1: fully aware of how painful this matrix is to manage, right?
• 12:14
  Speaker 1: So they are trying to engineer their way out of
• 12:16
  Speaker 1: all this unpredictability.
• 12:17
  Speaker 2: Oh, absolutely.
• 12:18
  Speaker 1: And that brings us to the 2026 landscape, specifically the
• 12:22
  Speaker 1: International Council for Harmonization, or ICH, and their Q12 guidelines.
• 12:27
  Speaker 2: Right. So the IC8s is a global initiative that brings
• 12:29
  Speaker 2: together regulatory authorities and the pharmaceutical industry to try and
• 12:32
  Speaker 2: create uniform scientific and technical guidelines. The Q12 guideline is
• 12:37
  Speaker 2: basically their framework for product lifecycle management.
• 12:40
  Speaker 1: And the most powerful mechanism it introduces is the PACMP,
• 12:45
  Speaker 1: the Post-Approval Change Management Protocol.
• 12:47
  Speaker 2: What's fascinating here is that a PACMP acts as a
• 12:50
  Speaker 2: negotiated forward-looking contract.
• 12:53
  Speaker 1: Break down the mechanics of this. How does a protocol
• 12:55
  Speaker 1: actually change the timeline we just discussed?
• 12:58
  Speaker 2: Well, instead of making a change, compiling all the evidence,
• 13:01
  Speaker 2: and then submitting it to see if the regulator accepts
• 13:03
  Speaker 2: your science, a PACMP allows you to agree on the
• 13:07
  Speaker 2: rules of the game before you even play.
• 13:09
  Speaker 1: Okay, give me a real-world scenario.
• 13:11
  Speaker 2: Sure. A company goes to the regulatory authority and says, hey,
• 13:14
  Speaker 2: we plan to change our testing equipment next year. If
• 13:17
  Speaker 2: we run three specific validation batches on the new equipment,
• 13:21
  Speaker 2: and they pass within a 2% margin of error, will
• 13:24
  Speaker 2: you accept that evidence as sufficient to approve the change?
• 13:27
  Speaker 1: Oh, I see. So you are agreeing prospectively on the studies,
• 13:31
  Speaker 1: the acceptance criteria, and the actual evidence package for a
• 13:34
  Speaker 1: future event.
• 13:35
  Speaker 2: Yes. The authority reviews the protocol, and if they agree,
• 13:38
  Speaker 2: you now have guaranteed predictability. When you actually execute the
• 13:41
  Speaker 2: change a year later, you just submit the data proving
• 13:44
  Speaker 2: you met the pre-agreed conditions.
• 13:45
  Speaker 1: That's huge.
• 13:46
  Speaker 2: It vastly accelerates the final review process because the scientific
• 13:50
  Speaker 2: debate has already been settled beforehand.
• 13:52
  Speaker 1: Okay, wait. Let me push back on this a bit.
• 13:55
  Speaker 2: Go for it.
• 13:55
  Speaker 1: If we are pre-agreeing on the science with this international guideline,
• 13:59
  Speaker 1: doesn't that just create a massive universal loophole? Like if
• 14:03
  Speaker 1: my core CMC team gets the EMA in Europe to
• 14:06
  Speaker 1: sign off on this PCMP protocol, can I just take
• 14:10
  Speaker 1: that signed agreement, waive it at the FDA or the
• 14:13
  Speaker 1: Japanese Health Authority, and demand they accept the change immediately.
• 14:18
  Speaker 1: Does this let companies bypass the local mapping entirely?
• 14:22
  Speaker 2: Not even slightly.
• 14:23
  Speaker 1: Really?
• 14:23
  Speaker 2: No, and the DDA Guide is explicit in warning change
• 14:25
  Speaker 2: management teams against making that exact assumption. A PCMP offers
• 14:29
  Speaker 2: scientific predictability. It does not offer regulatory universalization. Ah.
• 14:35
  Speaker 1: So the local administrative laws still went out in the end.
• 14:38
  Speaker 2: Always. ICH guidelines are designed to harmonize the scientific expectations, sure.
• 14:42
  Speaker 2: but the implementation of those tools depends entirely on regional,
• 14:46
  Speaker 2: sovereign regulatory framework.
• 14:47
  Speaker 1: How's that look in practice right now?
• 14:49
  Speaker 2: Well, the EU, for example, just issued a revised question
• 14:52
  Speaker 2: and answer document on PCMPs that became legally effective in
• 14:57
  Speaker 2: mid-January 2026. That document aligns the use of these protocols
• 15:01
  Speaker 2: strictly with their new variations environment.
• 15:04
  Speaker 1: Meaning, even if you have a pre-agreed protocol in the science,
• 15:08
  Speaker 1: Europe is still going to force you to file it
• 15:10
  Speaker 1: through their specific Type I or Type II pathways.
• 15:14
  Speaker 2: Exactly. And the U.S. is still going to make you
• 15:16
  Speaker 2: file it through their supplement pathways. The strategic value of
• 15:19
  Speaker 2: the PCMP is just that you eliminate the risk of
• 15:22
  Speaker 2: a regulatory authority rejecting your scientific methodology after you've spent
• 15:26
  Speaker 2: millions of dollars executing it.
• 15:28
  Speaker 1: You know the science will be accepted, at least.
• 15:30
  Speaker 2: Right. But the administrative pathway to submit that science and
• 15:34
  Speaker 2: the actual timelines for when you can legally implement it
• 15:36
  Speaker 2: still vary wildly by country.
• 15:38
  Speaker 1: Which brings us to the actual humans executing this whole strategy.
• 15:41
  Speaker 1: Because I think there is a common assumption that a
• 15:44
  Speaker 1: regulatory variation is just a paperwork exercise handled entirely by
• 15:48
  Speaker 1: the regulatory affairs department.
• 15:50
  Speaker 2: Oh, that's a huge misconception.
• 15:51
  Speaker 1: Right. People think they just sit in a silo, fill
• 15:53
  Speaker 1: out the local forms and hit send. But looking at
• 15:57
  Speaker 1: the source material, a successful change requires breaking down silos
• 16:01
  Speaker 1: across four massive, distinct internal teams.
• 16:05
  Speaker 2: Yeah, regulatory affairs is really just the translation engine at
• 16:08
  Speaker 2: the end of the line. The heavy lifting starts much,
• 16:11
  Speaker 2: much earlier.
• 16:13
  Speaker 1: Walk me through the teams.
• 16:14
  Speaker 2: First, you have the quality team. They own the pharmaceutical
• 16:17
  Speaker 2: quality system. Their mandate is pure compliance, basically ensuring that
• 16:22
  Speaker 2: any change is appropriately assessed, controlled, and documented according to
• 16:26
  Speaker 2: good manufacturing practices.
• 16:28
  Speaker 1: Okay, so quality polices the internal standards, right? Then who
• 16:32
  Speaker 1: is actually building that worst-case scenario data package we talked about?
• 16:36
  Speaker 2: That would be the CMC Team Chemistry Manufacturing and Controls.
• 16:40
  Speaker 2: They are the scientific engine. They establish the justification, figure
• 16:44
  Speaker 2: out the comparability protocols, run the validation requirements, and assess
• 16:47
  Speaker 2: the impact on the drug stability over time.
• 16:50
  Speaker 1: So they build the core dossier.
• 16:52
  Speaker 2: Yes, which is then handed off to Regulatory Affairs.
• 16:55
  Speaker 1: And they do the translation. Right.
• 16:57
  Speaker 2: Regulatory Affairs takes that scientific core... and translates it into
• 17:01
  Speaker 2: the legal language required by 50 different frameworks. They determine
• 17:05
  Speaker 2: the local classifications, map the submission routes, and calculate the
• 17:09
  Speaker 2: exact implementation eligibilities for every single registration.
• 17:13
  Speaker 1: And finally, the team that actually has to deal with
• 17:16
  Speaker 1: the physical fallout of all this paperwork, supply chain. Oh, man.
• 17:21
  Speaker 1: This is where the nightmare scenario of split inventory takes shape,
• 17:25
  Speaker 1: isn't it?
• 17:25
  Speaker 2: Supply chain arguably has the most complex logistical task in
• 17:29
  Speaker 2: the entire company. Because of everything we've discussed, you know,
• 17:32
  Speaker 2: the varying local classifications, the differing wait times, the prior
• 17:36
  Speaker 2: approvals versus the tail weight and doing models. Supply chain
• 17:39
  Speaker 2: has to navigate divergent eligibilities on a daily basis.
• 17:43
  Speaker 1: I'm just imagining standing in a massive global distribution warehouse.
• 17:47
  Speaker 1: A forklift driver is holding a pallet of the newly
• 17:50
  Speaker 1: manufactured drug featuring that updated microfilter. Market A, let's say Germany,
• 17:54
  Speaker 1: has officially cleared the new product. Their 30-day clock ran out.
• 17:58
  Speaker 1: But market B... right next door in Switzerland, shares the
• 18:01
  Speaker 1: exact same shipping route, but they legally require a prior
• 18:05
  Speaker 1: approval that just hasn't arrived yet.
• 18:07
  Speaker 2: Exactly. And to Switzerland, that pallet of new drugs is
• 18:10
  Speaker 2: legally considered counterfeit, unapproved material.
• 18:13
  Speaker 1: Which means supply chain has to manage and segregate old
• 18:16
  Speaker 1: versus new inventory based on pending regulatory wait times across
• 18:21
  Speaker 1: dozens of markets simultaneously.
• 18:23
  Speaker 2: Yes. And if regulatory affairs achieves an implementation eligibility in Germany...
• 18:29
  Speaker 2: but fails to immediately and clearly communicate that status to
• 18:32
  Speaker 2: supply chain, you end up with stockouts in Germany. Or worse,
• 18:35
  Speaker 2: you accidentally ship the new product to Switzerland, triggering a
• 18:38
  Speaker 2: massive international compliance violation.
• 18:41
  Speaker 1: Managing all of that, the tracking matrix, the local nuances,
• 18:44
  Speaker 1: the running countdowns, and the jewel inventory segregation across 50 markets.
• 18:48
  Speaker 1: I mean, that sounds completely impossible to do on a
• 18:50
  Speaker 1: traditional spreadsheet.
• 18:51
  Speaker 2: It really is.
• 18:52
  Speaker 1: So what does this all mean for the industry? How
• 18:54
  Speaker 1: are companies in 2026 actually surviving this level of fragmentation?
• 18:59
  Speaker 2: It means that variation management has transcended being just a
• 19:02
  Speaker 2: chemistry challenge or even just a legal challenge. It is
• 19:05
  Speaker 2: fundamentally a regulatory data challenge now.
• 19:07
  Speaker 1: That makes a lot of sense.
• 19:08
  Speaker 2: The industry has really reached a breaking point with isolated
• 19:12
  Speaker 2: submission trackers. You know, those massive spreadsheets owned by one manager.
• 19:17
  Speaker 2: When that manager goes on vacation, the entire global supply
• 19:20
  Speaker 2: chain visibility just freezes.
• 19:23
  Speaker 1: Yeah, you definitely can't run a multi-billion dollar logistics operation
• 19:26
  Speaker 1: on a static document.
• 19:28
  Speaker 2: You cannot. The sheer volume of variables requires dynamic logic.
• 19:32
  Speaker 2: This is why the industry is rapidly shifting toward integrated
• 19:35
  Speaker 2: lifecycle software. The guide actually highlights systems like D.G. Rager's
• 19:39
  Speaker 2: Vitalik LC, which shifts the whole paradigm from tracking paperwork
• 19:44
  Speaker 2: to maintaining portfolio-level data visibility.
• 19:47
  Speaker 1: How does software actually solve the split inventory nightmare? practically speaking?
• 19:51
  Speaker 2: By creating a live ecosystem based on a single source
• 19:54
  Speaker 2: of truth. Vitalik LC connects the product data, the market
• 19:57
  Speaker 2: registration details, the specific variation status, and the implementation deadlines
• 20:01
  Speaker 2: into one unified dashboard.
• 20:03
  Speaker 1: So everyone sees the same thing. Right.
• 20:05
  Speaker 2: Regulatory, quality, CMC, and supply chain are all looking at
• 20:10
  Speaker 2: the exact same data points in real time.
• 20:13
  Speaker 1: So it eliminates the communication lag. When the EU's 30-day
• 20:16
  Speaker 1: wait-and-do period expires for Germany, the software automatically flips the
• 20:20
  Speaker 1: status from pending to eligible.
• 20:23
  Speaker 2: Exactly.
• 20:24
  Speaker 1: And the supply chain team sees a green light on
• 20:26
  Speaker 1: their dashboard instantly. The forklift driver knows the pallet is
• 20:29
  Speaker 1: legal for Germany, and they don't have to wait for
• 20:32
  Speaker 1: someone in regulatory affairs to remember to send an email.
• 20:34
  Speaker 2: Precisely. In 2026, the competitive advantage in global pharma isn't
• 20:38
  Speaker 2: just about developing the best molecule anymore. It is about
• 20:42
  Speaker 2: having the most agile visibility into your regulatory status. You
• 20:46
  Speaker 2: cannot force regulatory harmony on the world, but you can
• 20:49
  Speaker 2: manage the variations through unified, automated data.
• 20:52
  Speaker 1: This has been such a revealing deep dive into a
• 20:54
  Speaker 1: world most people never see. And honestly, whether you are
• 20:57
  Speaker 1: managing global pharmaceutical supply chains, rolling out massive enterprise software,
• 21:02
  Speaker 1: or Just trying to navigate a complex team project across
• 21:05
  Speaker 1: different departments, the core lesson translates perfectly.
• 21:08
  Speaker 2: Oh, for sure.
• 21:09
  Speaker 1: A global strategy must anchor itself to a single source
• 21:12
  Speaker 1: of truth. In this case, the core scientific justification. But
• 21:16
  Speaker 1: ultimate success depends entirely on respecting and adapting to local
• 21:20
  Speaker 1: execution realities. You cannot bully 50 different global authorities into
• 21:25
  Speaker 1: accepting one universal rulebook. You can only master the fragmentation
• 21:29
  Speaker 1: through extreme visibility and airtight coordination.
• 21:33
  Speaker 2: It does raise a pretty fascinating question about the immediate future, though.
• 21:36
  Speaker 1: Oh, what's that?
• 21:37
  Speaker 2: Well, if regulatory software like Vitalik LC is already successfully
• 21:42
  Speaker 2: centralizing this incredibly complex compliance logic, how far are we
• 21:48
  Speaker 2: from a reality where pharmaceutical AI systems begin directly interfacing
• 21:52
  Speaker 2: with the AI systems of global health authorities?
• 21:54
  Speaker 1: Oh, wow.
• 21:55
  Speaker 2: Yeah. Yeah. Imagine a system that autonomously negotiates implementation dates,
• 21:59
  Speaker 2: submits the necessary PCMP evidence packages, and clears those tell, wait,
• 22:04
  Speaker 2: and do hurdles across 50 countries in real time, all
• 22:06
  Speaker 2: without a human regulatory team ever drafting a single email.
• 22:10
  Speaker 1: That is wild.
• 22:10
  Speaker 2: The science is already locked in these systems, right? So
• 22:13
  Speaker 2: how long until the administrative deployment is entirely autonomous?
• 22:15
  Speaker 1: That is a staggering thought to end on. I think
• 22:18
  Speaker 1: we're going to need a whole separate deep dive just
• 22:20
  Speaker 1: to unpack the implications of autonomous regulatory negotiation. Thank you
• 22:25
  Speaker 1: for walking us through this hidden matrix. And thank you
• 22:28
  Speaker 1: to everyone for listening. We'll see you next time.